Agios Pharma (AGIO) Tops Q4 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Janney Montgomery Scott Upgrades Agios Pharma (AGIO) to Buy
February 16, 2017 1:39 PM ESTJanney Montgomery Scott earlier upgraded Agios Pharma (NASDAQ: AGIO) from Neutral to Buy with a price target of $57.00.
For an analyst ratings summary and ratings history on Agios Pharma click here. For more ratings news on Agios Pharma click here.
Shares of Agios Pharma closed at $46.12 yesterday.
... More